Navigation Links
Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
Date:8/17/2011

"estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... of assets related to the ion channel biology platform ... previously been obtained as part of Pfizer,s 2011 acquisition ... Pfizer,s rights to the "Icagen" name and trademark.  XRPro ... comprehensive services for ion channel and transporter drug discovery, ...
(Date:7/2/2015)... , 2 de julio de 2015 ... ADN de alto rendimiento en ... American College of Pathologists (CAP). La instalación de BGI en ... laboratorio de secuenciación de próxima generación que recibe la ... el más alto estándar en prácticas de laboratorio clínico. ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
(Date:7/4/2015)... ... July 04, 2015 , ... Chronic Neck Pain. Neck pain is ... located in the neck. Another 19% suffer from head, migraine, or facial pain, in ... that 45% of American workers must deal with neck pain. Strategies for ...
(Date:7/3/2015)... ... July 03, 2015 , ... On June ... a new SEO training system called "Page One Engine" . The program, ... has received glowing reviews from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national chief nursing officer recruitment for ... firms in the healthcare industry, B. E. Smith has recently placed more than ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... First ... United States, named Mariah N. Manzanares, MD as the new Medical Director of its ... facility medical director of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:7/2/2015)... , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. ... The opening is the first sweetFrog store located in Mississippi. The premium frozen yogurt ... in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS 38652, ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2
... News) -- Over the last decade, the number of ... a smaller slice of the 10-year hospitalization rate than ... finding stems from the largest effort launched in the ... patterns. In the latest year, Medicare hospitalizations totaled about ...
... University of Houston (UH) students, two from the ... College of Social Work (GCSW), will lead health-related ... 2011-2012 under the Houston-Galveston Schweitzer Fellows Program. ... program sites throughout the U.S., the newly selected ...
... Calif. Evolutionary geneticist John H. Werren will give ... Riverside on Monday, May 16. His lecture, titled "Using ... speciation," will take place at 4 p.m. in the Genomics Auditorium, ... 5 p.m. in the Department of Entomology lobby. Both ...
... (HealthDay News) -- ,Bedbugs carrying two types of drug-resistant ... discovery in light of the resurgence of bedbugs in ... years. The researchers tested five bedbugs collected from ... Columbia known as Downtown Eastside, which has high rates ...
... News) -- The flakes of human skin in household dust ... Humans shed their entire outer layer of skin every ... study, published in the May issue of the journal ... oils such as cholesterol and squalene, are a major contributor ...
... exercise all have received their fair share of blame for ... to a University of Illinois researcher, public health enemy No. ... one staple of modern life most Americans can,t seem to ... Jacobson, a professor of computer science and the director of ...
Cached Medicine News:Health News:Fewer Medicare Patients Hospitalized for Heart Trouble 2Health News:3 University of Houston students chosen as Albert Schweitzer Fellows 2Health News:Evolutionary geneticist to give talk at UC Riverside on how biological species evolve and adapt 2Health News:Bedbugs May Transmit Drug-Resistant Bacteria 2Health News:Shed Skin in Dust May Reduce Indoor Air Pollution 2Health News:Study: Surge in obesity correlates with increased automobile usage 2Health News:Study: Surge in obesity correlates with increased automobile usage 3Health News:Study: Surge in obesity correlates with increased automobile usage 4
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
... Normal and Abnormal Control ... of vWF, D-dimer and ... STA© Analyzers. For use ... (#0518),STA© LIATEST© D-DI (#0515) ...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: